Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

NCT06822543 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT06822543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06822543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2025
Completion date
November 1, 2028
Enrollment
46 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, lung cancer, non small cell lung cancer